Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
It carries an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
Presented at the American Heart Associations 2023 Scientific Sessions (1113 November, Philadelphia, USA), the results of the SELECT trial showed that overweight or obese people without diabetes taking semaglutide for more than three years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight
Semaglutide belongs to the class of medications called GLP-1 receptor agonists
GLP-1R Trp 78 , Pro 90 , Trp 91 , and His 212 could form a hydrophobic region with GLP-1 Phe 28 , Ile 29 , Trp 31 , Leu 32 , and Val 33 , and GIPR Leu 35 , Trp 39 , Tyr 36 , Met 67 , Tyr 87 , Trp 90 , and His 115 could form a hydrophobic region with GIP Phe 22 , Val 23 , Trp 25 , Leu 26 , and Leu 27
Regular Monitoring and Adjustments Regular monitoring by a healthcare provider or a nutritionist is vital
US$ 24.82
US$ 26.81
US$ 26.26
US$ 22.03
